High and low-risk febrile neutropenic patients

被引:2
|
作者
Blot, F [1 ]
Nitenberg, G [1 ]
机构
[1] Inst Gustave Roussy, Serv Reanimat Med Chirurgicale, F-94805 Villejuif, France
来源
PRESSE MEDICALE | 2004年 / 33卷 / 07期
关键词
D O I
10.1016/S0755-4982(04)98634-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Identification of low-risk patients These patients exhibit a low probability of dying (risk equal or lesser than 1%) and of developing major complications (risk to the order of 5%). A clinical model developed by Talcott et al. considers at low risk patients at home when the fever starts, without severe co-morbidity and in whom the neoplasia is under control. A prognostic score was established by the MASCC (Multinational Association for Supportive Care in Cancer); it is based on objectively weighted and selected variables. In comparaison, the Talcott's classification appears more restrictive (2.5-fold less patients at low risk) but also that it supplies greater safety Identification of high-risk patients All the severity scores used in intensive care have their limits. However, the repeated calculation of severity scores (at 48 and 72 hours) might lead to an improvement in their predictive value. The number of organ dysfunction could also be used because the latter provides supplementary clinical information and hence the development of organ dysfunction scores over the past few years. For febrile neutropenic patients other than in intensive care, the interest of the severity scores and organ dysfunction scores appears limited.
引用
收藏
页码:467 / 473
页数:7
相关论文
共 50 条
  • [21] Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer
    Sheng Zhang
    Qing Wang
    Yun Ling
    Xichun Hu
    BMC Cancer, 15
  • [22] The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
    Klastersky, J
    Paesmans, M
    Rubenstein, EB
    Boyer, M
    Elting, L
    Feld, R
    Gallagher, J
    Herrstedt, J
    Rapoport, B
    Rolston, K
    Talcott, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 3038 - 3051
  • [23] CISNE versus MASCC: Identifying low risk febrile neutropenic patients
    Mohindra, Ritin
    Mathew, Roshan
    Yadav, Sakshi
    Aggarwal, Praveen
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2020, 38 (11): : 2259 - 2263
  • [24] Predictive factors of bacteraemia in low-risk patients with febrile neutropenia
    Ahn, Shin
    Lee, Yoon-Seon
    Chun, Yeon Hee
    Lim, Kyung Soo
    Kim, Won
    Lee, Jae-Lyun
    EMERGENCY MEDICINE JOURNAL, 2012, 29 (09) : 715 - 719
  • [26] HIGH AND LOW-RISK TIA PATIENTS
    PRENCIPE, M
    STROKE, 1984, 15 (04) : 758 - 758
  • [27] Low dose continuous infusion ceftazidime monotherapy in low risk febrile neutropenic patients.
    Marshall, E
    Smith, DB
    O'Reilly, SM
    Murray, A
    Kelly, V
    Clark, PI
    BRITISH JOURNAL OF CANCER, 1999, 80 : 19 - 19
  • [28] The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
    Jean Klastersky
    Marianne Paesmans
    Supportive Care in Cancer, 2013, 21 : 1487 - 1495
  • [29] The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
    Klastersky, Jean
    Paesmans, Marianne
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1487 - 1495
  • [30] Early discharge and ambulatory care of low-risk patients with neutropenic fever in Australia
    Hocking, C.
    Taylor, A.
    Hayward, A.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (05) : 591 - 595